Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension

Study Purpose

Chronic thromboembolic pulmonary hypertension [CTEPH] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty [BPA] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area [FCSA] is recovered during BPA. We plan to measure FCSAIn CTEPH patients, before and after a session of BPA.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.

Exclusion Criteria:

- Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, Presence of patent foramen ovale

Trial Details

Trial ID:

This trial id was obtained from, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Jewish General Hospital
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries Canada

The disease, disorder, syndrome, illness, or injury that is being studied.

Hypertension, Pulmonary, Pulmonary Thromboembolisms
Additional Details

Chronic thromboembolic pulmonary hypertension [CTEPH] affects approximately 3% of patients with a prior pulmonary embolism. In CTEPH patients, the acute pulmonary emboli do not resolve but instead become organized in the pulmonary artery walls causing physical luminal obstruction and impeding forward blood flow. Pulmonary vascular resistance rises, and right heart failure can ultimately develop. Currently, there are 3 therapeutic options for treating CTEPH: 1) pulmonary thromboendarterectomy involving surgical removal of the clots; 2) balloon pulmonary angioplasty involving opening of the narrow areas using angioplasty balloons; 3) medical therapy for distal disease using the soluble guanylate cyclase stimulator riociguat. Balloon pulmonary angioplasty (BPA), depending on the number of narrow pulmonary artery segments that are opened, can provide immediate hemodynamic benefit in appropriate patients. Although the hemodynamics usually do not completely normalize after a single BPA session, cardiac output may increase and mean pulmonary artery pressure may fall. It is unclear how much pulmonary microvasculature must be restored to obtain this benefit, both in terms of number of segments, and in terms of the amount of downstream pulmonary microvasculature that must be regained. We have developed a technique in humans that assesses functional capillary surface area (FCSA). It involves measuring the metabolism of injected trace quantities of 3H-benzoyl Phe-Ala-Pro (BPAP), as the peptide passes through the lung circulation, and interacts with the capillary endothelial surface area. We have established the range of normal in humans, studied the effects of exercise, and explored the reduction in FCSA in disease, including various types of pulmonary hypertension. Most germane to the present study, our previous work (Orfanos et al J Throm Hemostas 2008) demonstrated that the downstream capillary bed in CTEPH is functionally normal but FCSA is reduced because of upstream arteriolar blockage by organized thrombi. The average FCSA in untreated CTEPH is decreased by approximately 50%. Some of this FCSA should be immediately available to accept blood flow (recruitment) once the corresponding upstream segmental pulmonary artery is reopened by BPA. Hypotheses: 1. The measured FCSA will immediately increase in CTEPH patients after BPA. 2. The amount of FCSA regained (recruited) will be proportional to the number of pulmonary arterial segments dilated. 3. The decrease in mean pulmonary arterial pressure towards normal may be a better indicator of FCSA regained than will be reduction in pulmonary vascular resistance. Techniques: All our routine techniques for BPA remain unchanged. The patients have a systemic arterial line and a pulmonary artery thermodilution catheter inserted for hemodynamic measurements prior to BPA, and the measurements are repeated after BPA. The only added procedure is that there will be 2 injections of 3H-BPAP via the "proximal" port of the thermodilution catheter, at the time of hemodynamic measurements pre-BPA (PRE) and post-BPA (POST). Systemic arterial blood will be collected at each timepoint for analysis of BPAP metabolism. Recruitment and Consent: The protocol has already been approved by the JGH IRB. Patients with newly diagnosed CTEPH who are deemed to be candidates for BPA will be approached in our Pulmonary Hypertension/CTEPH clinic. The research procedures and purpose will be explained and they will be given a consent form to review, and their questions will be answered. Should they agree to participate, the consent form will be signed and they will be included in the study. Sample size: Because BPAP metabolism will be measured pre and post BPA in the same patient, they will act as their own controls. We are planning a study of a continuous response variable from matched pairs of study subjects. Prior data indicate that the baseline standard deviation of FCSA in the CTEPH population is 784. If the true FCSA difference in the mean response of matched pairs is 505 (33% increase in FCSA), we will need to study 27 subjects to be able to reject the null hypothesis that this response difference is zero with probability (power) 0.9. If the mean response is 765 (50% increase), we will need to study 13 subjects. The Type I error probability associated with this test of this null hypothesis is 0.05. We will assess the magnitude of response after 10 subjects are completed and, based on that, reduce the n where possible. But we have planned to study at least 40 subjects if needed.

Arms & Interventions


Experimental: Pre and post BPA


Other: - Measurement of pulmonary functional capillary surface area

Measurement of transpulmonary metabolism of trace injected doses of benzoyl-Phe-Ala-Pro

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

David Langleben, Montreal, Quebec, Canada




David Langleben

Montreal, Quebec, H3W 2C4

Site Contact

David Langleben


For more information, please contact PHA at and refer to the terms of service below.

Submit Feedback

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation in a clinical trial or study.